A detailed history of Geode Capital Management, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,622,221 shares of ADGI stock, worth $5.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,622,221
Previous 1,635,901 0.84%
Holding current value
$5.37 Million
Previous $5.41 Million 0.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
N/A
-13,680 Reduced 0.84%
1,622,221 $5.37 Million
Q2 2024

Aug 09, 2024

BUY
N/A
1,024,442 Added 167.54%
1,635,901 $5.41 Million
Q1 2024

May 13, 2024

BUY
N/A
30,369 Added 5.23%
611,459 $2.02 Million
Q4 2023

Feb 13, 2024

BUY
N/A
37,430 Added 6.88%
581,090 $1.92 Million
Q3 2023

Nov 13, 2023

BUY
N/A
26,066 Added 5.04%
543,660 $1.8 Million
Q2 2023

Aug 11, 2023

SELL
N/A
-519,603 Reduced 50.1%
517,594 $1.71 Million
Q1 2023

May 15, 2023

BUY
N/A
15,342 Added 1.5%
1,037,197 $3.43 Million
Q4 2022

Feb 13, 2023

BUY
$3.08 - $4.05 $125,072 - $164,462
40,608 Added 4.14%
1,021,855 $1.53 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $4.83 $779,791 - $1.27 Million
262,556 Added 36.53%
981,247 $3.07 Million
Q2 2022

Aug 12, 2022

BUY
$2.54 - $4.52 $200,654 - $357,070
78,998 Added 12.35%
718,691 $2.36 Million
Q1 2022

May 13, 2022

BUY
$3.81 - $10.77 $997,869 - $2.82 Million
261,908 Added 69.33%
639,693 $2.92 Million
Q4 2021

Feb 11, 2022

BUY
$6.35 - $47.04 $36,537 - $270,668
5,754 Added 1.55%
377,785 $2.74 Million
Q3 2021

Nov 12, 2021

BUY
$20.88 - $56.08 $7.77 Million - $20.9 Million
372,031 New
372,031 $15.7 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.